Blood Outgrowth Endothelial Cells (BOECs) and Megakaryocytes (MKs) for in vitro studies of hemostatic and secretory function

Erasmus MC0 个研究点目标入组 300 人开始时间: 待定最近更新: 2024年2月28日

试验速览

暂无简介。

•???? Prior diagnosis of VWD, low VWF, inherited platelet function defects, bleeding of unknown
•cause or genetic disorders in which dysfunction of the secretory pathway has been
•implicated in disease pathogenesis.
•???? For patients =16 years old; written informed consent
•???? For patients 12-15 years old; written informed consent from both the patient and their
•parent(s)/legal guardian(s)
•???? For patients <12 years old; written informed consent from their parent(s)/legal guardian(s)
•Family members
•???? Age 18 years or older
•???? Family member of a patient with VWD, low VWF, inherited platelet function defects,
•bleeding of unknown cause or genetic disorders in which dysfunction of the secretory
•pathway has been implicated in disease pathogenesis.
•???? Family members may or may not be affected.
•Healthy controls
•???? Age 18 years or older
•???? Not previously diagnosed with VWD, low VWF, inherited platelet function defects, bleeding
•of unknown cause or genetic disorders in which dysfunction of the secretory pathway has
•been implicated in disease pathogenesis.

•A potential subject who meets any of the following criteria will be excluded from participation
•in this study:
•???? Unable to give written informed consent.
•???? Use of medication that can compromise platelet function or hemostasis.

发起方